Get the Stockscreener App
6.87
3.92%
-0.28
Zevra Therapeutics Inc stock is traded at $6.87, with a volume of 363.61K.
It is down -3.92% in the last 24 hours and down -14.23% over the past month.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
See More
Previous Close:
$7.15
Open:
$7.11
24h Volume:
363.61K
Relative Volume:
0.82
Market Cap:
$377.73M
Revenue:
$27.46M
Net Income/Loss:
$-46.05M
P/E Ratio:
-5.3256
EPS:
-1.29
Net Cash Flow:
$-33.83M
1W Performance:
-1.58%
1M Performance:
-14.23%
6M Performance:
-19.56%
1Y Performance:
+51.99%
1-Day Range:
$6.85
$7.11
1-Week Range:
$6.7701
$7.27
52-Week Range:
$4.20
$9.76
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Name
Zevra Therapeutics Inc
Sector
Industry
Phone
(321) 939-3416
Address
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Compare ZVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
6.87 | 377.73M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-07-24 | Initiated | Guggenheim | Buy |
| Sep-24-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-24-24 | Reiterated | Maxim Group | Buy |
| Apr-02-24 | Reiterated | Maxim Group | Buy |
| Mar-12-24 | Initiated | William Blair | Outperform |
| Mar-17-23 | Initiated | Maxim Group | Buy |
View All
Zevra Therapeutics Inc Stock (ZVRA) Latest News
Zevra calls for stockholder support against board influence bid - Investing.com
Zevra Therapeutics (ZVRA) Prepares for 2025 Annual Meeting, Advocates for Board Stability | ZVRA Stock News - GuruFocus
Zevra calls for stockholder support against board influence bid By Investing.com - Investing.com India
Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders | ZVRA Stock News - GuruFocus
Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders - GlobeNewswire
Form DEFC14A ZEVRA THERAPEUTICS, INC. Filed by: ZEVRA THERAPEUTICS, INC. - StreetInsider
Zevra Therapeutics (ZVRA) Reveals Key Insights into Niemann-Pick Type C Treatment | ZVRA Stock News - GuruFocus
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism | ZVRA Stock News - GuruFocus
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism - GlobeNewswire
Breakthrough Study Uncovers MIPLYFFA's Mechanism for Treating Fatal Genetic Disease NPC - Stock Titan
Institutional investors may overlook Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) recent US$44m market cap drop as long-term gains remain positive - simplywall.st
Zevra Announces Closing Of Sale Of Rare Pediatric Disease Priority Review Voucher - MarketScreener
Zevra Therapeutics Nets $150 Million From US FDA Voucher Sale, Increases Cash Reserves - marketscreener.com
Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million - GlobeNewswire
$150M FDA Voucher Sale Transforms Zevra's Financial Position: Rare Disease Success Story - Stock Titan
Will the tariffs lead to a recession? Here's how to know if we're in one - The Globe and Mail
Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline - MSN
(ZVRA) Technical Data - news.stocktradersdaily.com
Zevra Therapeutics: Mixed Feelings On Miplyffa Approval (NASDAQ:ZVRA) - Seeking Alpha
Zevra therapeutics director Corey Watton buys $2,351 in stock By Investing.com - Investing.com Australia
Zevra therapeutics director Corey Watton buys $2,351 in stock - Investing.com
Zevra Therapeutics Asks Shareholders to Reject Director Nominees by Activist Investor - MarketScreener
Zevra Therapeutics Files Preliminary Proxy - The Manila Times
Proxy Fight Erupts at Zevra: Former CEO Challenges $150M Cash-Rich Biotech - Stock Titan
Trend Tracker for (ZVRA) - news.stocktradersdaily.com
John Bode Bought 33% More Shares In Zevra Therapeutics - simplywall.st
Zevra Therapeutics Independent Director Acquires 33% More Stock - Yahoo Finance
Insider Buying: John Bode Acquires Additional Shares of Zevra Th - GuruFocus
Zevra therapeutics director Bode acquires $79,624 in stock By Investing.com - Investing.com Canada
Zevra therapeutics director Bode acquires $79,624 in stock - Investing.com
ZEVRA THERAPEUTICS Director John B Bode Acquires 10,000 Shares - TradingView
Woodline Partners LP's Strategic Acquisition of Zevra Therapeuti - GuruFocus.com
Zevra Therapeutics’ SWOT analysis: stock poised for growth amid rare disease focus - Investing.com Australia
Zevra Therapeutics’ SWOT analysis: stock poised for growth amid rare disease focus By Investing.com - Investing.com South Africa
HC Wainwright Predicts Lower Earnings for Zevra Therapeutics - Defense World
(ZVRA) On The My Stocks Page - news.stocktradersdaily.com
Guggenheim Forecasts Strong Price Appreciation for Zevra Therapeutics (NASDAQ:ZVRA) Stock - Defense World
Zevra Therapeutics (NASDAQ:ZVRA) Earns Overweight Rating from Cantor Fitzgerald - Defense World
Roth Capital Predicts Weaker Earnings for Zevra Therapeutics - Defense World
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Canaccord raises Zevra Therapeutics target to $25; Keeps Buy rating By Investing.com - Investing.com Australia
Zevra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Optimistic Buy Rating for Zevra Therapeutics Driven by Miplyffa Launch and Strategic Financial Moves - TipRanks
Canaccord raises Zevra Therapeutics target to $25; Keeps Buy rating - Investing.com India
Zevra Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Zevra Therapeutics’ Earnings Call Highlights Success and Growth - TipRanks
Sector Update: Health Care -March 12, 2025 at 01:43 pm EDT - Marketscreener.com
Cantor Fitzgerald maintains $25 target on Zevra Therapeutics stock - Investing.com
Zevra Therapeutics stock target raised to $18 at JMP - Investing.com India
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2024 Earnings Call Transcript - Insider Monkey
Cantor Fitzgerald maintains $25 target on Zevra Therapeutics stock By Investing.com - Investing.com South Africa
Zevra Therapeutics Inc Stock (ZVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):